• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, July 29, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

University of Dundee Drug Discovery Unit license USP15 assets to Corbin Therapeutics

Bioengineer by Bioengineer
June 5, 2019
in Health
Reading Time: 2 mins read
0
ADVERTISEMENT
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Deal to develop possible new treatments for neuroinflammation-based disorders, including multiple sclerosis

IMAGE

Credit: University of Dundee

The University of Dundee Drug Discovery Unit is delighted to announce it has licensed assets to Corbin Therapeutics to develop possible new treatments for neuroinflammation-based disorders, including multiple sclerosis (MS).

MS is a disease of the central nervous system in which inflammation causes damage to nerve cells and the myelin sheath which surrounds them. The condition affects 2.2 million people globally, including more than 100,000 people in the UK, and is more prevalent in women than men. Diagnosis often occurs at around 30 years of age with a variety of symptoms including loss of balance and dizziness, fatigue, pain, tremors, vision problems, speech problems, and bladder problems.

A ubiquitin-specific protease, USP15, has been shown to be key in the neuroinflammation pathogenesis. Corbin Therapeutics, a Montreal-based biotech company, was established to exploit this finding and uses a proprietary drug discovery platform to identify and validate novel small molecule inhibitors of USP15.

This License Agreement builds upon an existing partnership between Corbin Therapeutics and the Drug Discovery Unit in Dundee. With support from the Medical Research Council, this partnership has delivered multiple series of drug-like compounds suitable for further development by Corbin.

Dr Julie Brady, Business Development Manager for the Drug Discovery Unit, stated, “We are committed to the translation of world-class biology into novel drug targets and candidate drugs and we work with partners globally to achieve this. The relationship with Corbin has created a transatlantic, multidisciplinary team working towards the discovery of new medicines for diseases associated with neuroinflammation.”

Sean MacDonald, CEO Corbin Therapeutics, said, “The team in Dundee have helped us move forward with a very promising discovery program targeting USP15. Corbin is now focused on developing novel drugs that have the potential to treat a number of diseases of unmet medical need and to deliver value for our shareholders.”

Financial details have not been disclosed.

###

Media Contact
Roddy Isles
r.isles@dundee.ac.uk

Original Source

http://www.dundee.ac.uk/news/2019/university-of-dundee-drug-discovery-unit-licenses-usp15-assets-to-corbin-therapeutics.php

Tags: BiochemistryBiotechnologyCell BiologyMedicine/HealthMolecular BiologyPharmaceutical SciencePharmaceutical Sciences
Share12Tweet7Share2ShareShareShare1

Related Posts

blank

Novel Plasma Synuclein Test Advances Parkinson’s Diagnosis

July 29, 2025
blank

Obesity’s Impact on Pancreatic Surgery Outcomes Compared

July 28, 2025

Virion Movement in Sialoglycan-Cleaving Respiratory Viruses

July 28, 2025

Bariatric Surgery’s Impact on Circulating S100A9

July 28, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    54 shares
    Share 22 Tweet 14
  • USF Research Unveils AI Technology for Detecting Early PTSD Indicators in Youth Through Facial Analysis

    42 shares
    Share 17 Tweet 11
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    45 shares
    Share 18 Tweet 11
  • Engineered Cellular Communication Enhances CAR-T Therapy Effectiveness Against Glioblastoma

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Novel Plasma Synuclein Test Advances Parkinson’s Diagnosis

Advancing Microbial Risk Assessment Through Detection Technology Evolution

Obesity’s Impact on Pancreatic Surgery Outcomes Compared

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.